×
ProKidney Net Cash Flow 2021-2025 | PROK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
ProKidney net cash flow from 2021 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
ProKidney Net Cash Flow 2021-2025 | PROK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
ProKidney net cash flow from 2021 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$68.8B
Chugai Pharmaceutical (CHGCY)
$68.7B
Takeda Pharmaceutical (TAK)
$48B
Daiichi Sankyo, - (DSNKY)
$47.8B
BeOne Medicines - (ONC)
$33.8B
Sandoz Group AG (SDZNY)
$27.6B
Summit Therapeutics (SMMT)
$19.5B
Merck (MKKGY)
$16.5B
Shionogi (SGIOY)
$14.7B
United Therapeutics (UTHR)
$13.8B
Neurocrine Biosciences (NBIX)
$13.3B
IPSEN (IPSEY)
$11.4B
Orion OYJ (ORINY)
$11.3B
Eisai (ESAIY)
$9.2B
Madrigal Pharmaceuticals (MDGL)
$9.2B
Corcept Therapeutics (CORT)
$7.3B
Grifols, S.A (GRFS)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.7B
Stevanato Group S.p.A (STVN)
$6.7B
Ono Pharmaceutical (OPHLF)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Soleno Therapeutics (SLNO)
$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.8B
NewAmsterdam Pharma (NAMS)
$2.8B
Hypermarcas (HYPMY)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Procaps Group, S.A (PROCF)
$2.4B
Centessa Pharmaceuticals (CNTA)
$2.3B
Ocular Therapeutix (OCUL)
$2.1B